TY - JOUR
T1 - Targeting tumor stromal cells through a PDGF-beta receptor binding carrier
AU - Prakash, Jai
AU - de Jong, Edwin
AU - Post, Eduard
AU - Mohammad, Ara K.
AU - Beljaars, Leonie
AU - Poelstra, Klaas
PY - 2010/11/20
Y1 - 2010/11/20
N2 - Tumor stromal cells significantly contribute to tumor growth and abundantly express platelet-derived growth factor-beta receptor (PDGF-βR). In this study, we targeted stromal as well as tumor cells using our PDGF-βR binding carrier (pPB-HSA). pPB-HSA showed PDGF-βR-specific binding in-vitro and, in-vivo it rapidly accumulated in C26 tumors in mice after i.v. injection. We conjugated doxorubicin to pPB-HSA and, the conjugate showed antitumor effects in-vitro in tumor and stromal cells and in-vivo in C26-tumor bearing mice.
AB - Tumor stromal cells significantly contribute to tumor growth and abundantly express platelet-derived growth factor-beta receptor (PDGF-βR). In this study, we targeted stromal as well as tumor cells using our PDGF-βR binding carrier (pPB-HSA). pPB-HSA showed PDGF-βR-specific binding in-vitro and, in-vivo it rapidly accumulated in C26 tumors in mice after i.v. injection. We conjugated doxorubicin to pPB-HSA and, the conjugate showed antitumor effects in-vitro in tumor and stromal cells and in-vivo in C26-tumor bearing mice.
UR - http://www.scopus.com/inward/record.url?scp=80052164636&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2010.07.088
DO - 10.1016/j.jconrel.2010.07.088
M3 - Article
C2 - 21529587
AN - SCOPUS:80052164636
VL - 148
SP - e116
JO - Journal of controlled release
JF - Journal of controlled release
SN - 0168-3659
IS - 1
ER -